19 May 2020
Cambridge Innovation Capital makes investment in PetMedix
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, is pleased to announce it has invested in PetMedix, a Cambridge, UK-based biopharmaceutical company developing antibody-based therapeutics for companion animals.
PetMedix has developed an innovative platform for the creation of naturally generated, fully species-specific therapeutic antibodies, enabling the discovery of its own veterinary medicines to target some of the most important clinical areas in animal health. The funding provided by CIC will be used to further the development of PetMedix’s unique platform and pipeline, and CIC is delighted to be supporting the Company’s exciting growth transition from biotechnology start-up to clinical-stage animal health company.
“We are delighted with our progress to date. Our platforms continue to improve and drug discovery is well underway. This additional investment not only brings a knowledgeable and well-respected investor into our syndicate, but will support us in our ambitions to build a world-class animal health company.”
Dr Tom WeaverPetMedix CEO
“CIC is thrilled to be investing in one of the leading emerging animal health companies. We are hugely impressed by the quality of the science underpinning PetMedix’s differentiated platform, and by the strong team leading their discovery and development programmes. These are challenging times for all sectors, but innovation in Cambridge remains robust in its ability to adapt and thrive in unprecedented circumstances, as exemplified by the work of PetMedix, and our team continues to offer its full support to these businesses.”
Robert TansleyPartner at CIC
- ENDS –
For more information please contact:
Cambridge Innovation Capital
Robert Tansley, Partner
+44 (0)1223 764875
Consilium Strategic Communications (City, financial PR)
+44 (0)20 3709 5700
About Cambridge Innovation Capital
Cambridge Innovation Capital (CIC) is a venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem. CIC is committed to building leading businesses from brilliant technologies. It combines a unique relationship with the University of Cambridge with deep financial and industry links to enable visionaries to build global, category-leading companies.
For more information please visit www.cic.vc or follow us on Twitter at @CIC_vc
Cambridge Innovation Capital Manager Limited (FRN: 913528) is an appointed representative of Duff & Phelps Securities Limited (FRN: 466588) which is authorised and regulated by the Financial Conduct Authority.
PetMedix™ is a Cambridge, UK based research and development stage biopharmaceutical company developing antibody-based therapeutics for companion animals. The growing team have over 30 years’ experience building platforms that can develop species-specific therapeutic antibodies.
Driven by the core value of improving the health and welfare of animals, PetMedix™ is taking the cutting edge of human medicine and using it to develop innovative new veterinary treatments against a wide range of clinical indications for dogs and for cats.
Twitter: @PetMedix, LinkedIn: PetMedix,
Facebook: @PetMedix, Instagram: @PetMedix